Ashland Inc. Reports Q4 2026 Results with Growth in Life Sciences and Personal Care
Ashland Inc. (ASH) reported fourth-quarter fiscal 2026 results characterized by a 4% year-over-year increase in net sales to $498 million, driven by volume growth and pricing improvements. The company saw significant strength in its Life Sciences and Personal Care segments, with the former achieving record adjusted EBITDA margins due to high-value technology platforms and the latter seeing an 8% sales increase led by biofunctional actives. Despite these gains, the Specialty Additives segment faced challenges, with adjusted EBITDA falling 31% due to lower manufacturing productivity and unfavorable absorption at the Hopewell facility. Looking ahead to fiscal 2027, Ashland provided optimistic guidance, projecting annual sales between $1.905 billion and $1.975 billion and adjusted EBITDA between $405 million and $435 million, supported by anticipated commercial momentum and manufacturing optimizations.